Time to progression · participants with advanced or metastatic muscle invasive bladder cancer
It is very uncertain whether immune checkpoint inhibitors changes time to disease progression Range of compared with any second‐line chemotherapy (very low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors may leads to lower discontinuation due to adverse events Range of compared with any second‐line chemotherapy (low certainty).
1 finding from 1 review
Health‐related quality of life · participants with advanced or metastatic muscle invasive bladder cancer
1 finding from 1 review
Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors probably leads to lower adverse events grade 3 to 5 Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
Time to death from bladder cancer · participants with advanced or metastatic muscle invasive bladder cancer
1 finding from 1 review
Time to progression · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors probably leads to higher time to disease progression Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors showed no clear difference in discontinuation due to adverse events Range of compared with any first‐line chemotherapy (low certainty).
1 finding from 1 review
Time to death from any cause Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors may leads to lower time to death from any cause Range of compared with any second‐line chemotherapy (low certainty).
1 finding from 1 review
Health‐related quality of life · participants with advanced or metastatic muscle invasive bladder cancer
1 finding from 1 review
Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors may leads to lower adverse events grade 3 to 5 Range of compared with any second‐line chemotherapy (low certainty).
1 finding from 1 review
Time to bladder cancer recurrence (absolute effect size estimates based on recurrence rate at 12 months)
Single‐dose intravesical chemotherapy instillation may leads to lower time to bladder cancer recurrence (absolute effect size estimates… compared with placebo or observation after nephroureterectomy (low certainty).
1 finding from 1 review
Time to death from UTUC5
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events
1 finding from 1 review
Time to death from any cause5
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific quality of life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Partcipants with bladder cancer undergoing radical cystectomy (male n = 314, female n = 87; age (interquartile range) 59 to 74)Country:…
Impact of extended showed no clear difference in time to death from any cause (absolute effect size estimates based… compared with standard lymph node dissection on overall survival among patients… (low certainty).
1 finding from 1 review
Time to death from bladder cancer · Partcipants with bladder cancer undergoing radical cystectomy (male n = 314, female n = 87; age (interquartile range) 59 to 74)Country:…
Impact of extended showed no clear difference in time to death from bladder cancer (absolute effect size estimates… compared with standard lymph node dissection on overall survival among patients… (low certainty).
1 finding from 1 review
Clavien‐Dindo grade ≥ 3 complications · Partcipants with bladder cancer undergoing radical cystectomy (male n = 314, female n = 87; age (interquartile range) 59 to 74)Country:…
It is very uncertain whether impact of extended changes clavien‐Dindo grade ≥ 3 complications compared with standard lymph node dissection on overall survival among patients… (very low certainty).
1 finding from 1 review
Time to recurrence · Partcipants with bladder cancer undergoing radical cystectomy (male n = 314, female n = 87; age (interquartile range) 59 to 74)Country:…
It is very uncertain whether impact of extended changes time to recurrence (absolute effect size estimates based on… compared with standard lymph node dissection on overall survival among patients… (very low certainty).
1 finding from 1 review
Clavien‐Dindo grade ≤ 2 complications8 · Partcipants with bladder cancer undergoing radical cystectomy (male n = 314, female n = 87; age (interquartile range) 59 to 74)Country:…
It is very uncertain whether impact of extended changes clavien‐Dindo grade ≤ 2 complications8 compared with standard lymph node dissection on overall survival among patients… (very low certainty).
1 finding from 1 review